Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience
Open Access
- 24 September 2014
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 90 (1), 27-30
- https://doi.org/10.1002/ajh.23858
Abstract
The outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory, with few available effective therapies. Increased understanding of the biology of the disease has led to the identification of novel therapeutic agents, several of which have been evaluated in recently conducted clinical trials. We sought to determine whether the introduction of these agents as well as modern supportive care measures has already translated to better outcomes. We examined the outcomes of 1,056 patients with AML in first relapse treated between January 1993 and December 2013 at our institution. As previously reported, the independent prognostic factors for survival after first relapse included age at relapse, cytogenetics, and duration of first complete remission. Upon multivariable analysis, treatment era was an independent predictor of survival, with significant improvement in overall survival between 2008 and 2013 as compared to prior time periods. Modern supportive care measures as well as participation in clinical trials of novel agents are already improving the outcomes in first relapse. Am. J. Hematol. 90:27–30, 2015.Keywords
Funding Information
- National Institutes of Health through a Cancer Center Support Grant (P30CA16672)
This publication has 21 references indexed in Scilit:
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationBlood, 2013
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapseHaematologica, 2010
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProceedings of the National Academy of Sciences, 2010
- Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐CBritish Journal of Haematology, 2010
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2007
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2005
- Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparisonLeukemia, 1998